NCT07146646View on ClinicalTrials.gov

Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

April 30, 2027

Conditions
Biliary Tract CancerBiliary Tract NeoplasmsCholangiocarcinomaGallbladder CancerGallbladder Carcinoma
Interventions
DRUG

Trifluridine/tipiracil

FTD/TPI will be taken by mouth on Days 1-5 of the 14-day treatment cycle. The starting does is 25mg/m2 twice per day.

DRUG

Oxaliplatin

Oxaliplatin is given on Day 1 of each 14-day cycle. It is given intravenously (by IV) over 2 hours.

Trial Locations (2)

44106

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

44195

Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER

collaborator

National Comprehensive Cancer Network

NETWORK